A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC).

Dhruv Bansal,Rachel Beck,Vivek K. Arora,Eric M. Knoche,Joel Picus,Melissa A. Reimers,Bruce J. Roth,James L. Gulley,Robert D. Schreiber,Russell K. Pachynski

A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC).

2021

Dhruv Bansal
Rachel Beck
Vivek K. Arora
Eric M. Knoche
Joel Picus
Melissa A. Reimers
Bruce J. Roth
James L. Gulley
Robert D. Schreiber
Russell K. Pachynski

TPS192Background: Despite robust advances in the use of immune checkpoint blockade (ICB) across multiple cancer types, responses in prostate cancer remain suboptimal. Overall response rates for sin...

Keywords:

Oncology
Blockade
Prostate cancer
Ipilimumab
Nivolumab
Medicine
Immune checkpoint
Prostvac
Internal medicine
Hormone sensitive prostate cancer
DNA vaccination

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations